LUND, SE / ACCESSWIRE / October 30, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces participation in the following conferences during Q4 2024:

Investors and Partnering Conferences

• ØU Life Science Investor Conference , October 30, Copenhagen
  Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments and upcoming catalysts to investors at 4.55 pm CET, as well as meet institutional investors during the day.

• BIO-Europe , November 4-6, Stockholm
  Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, and Johan Giléus, Chief Financial Officer of Alligator Bioscience, will attend the conference to meet investors and potential strategic partners.

• Jefferies London Healthcare Conference, November 19-21, London
  Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, and Johan Giléus, Chief Financial Officer of Alligator Bioscience, will attend the conference to meet investors and potential strategic partners. The Jefferies London Healthcare Conference is one of the most prominent event in Europe and hosted over 800 healthcare companies, 3,500 attendees, and 7,900 investor and business-to-business meetings in 2023.

• DNB Nordic Healthcare Conference, November 26, Oslo
  Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, and Johan Giléus, Chief Financial Officer of Alligator Bioscience will attend the conference to meet investors and potential strategic partners. Søren Bregenholt will present the company, its latest developments and upcoming catalysts to investors at 1:30 pm CET.

Medical Conference

• Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting , November 6-10, Houston

  • Dr Thomas Marron will present preliminary results from the Phase 1 dose escalation trial with candidate ALG.APV-527 in a poster entitled " Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity " on Friday, November 8.

  • Ida Uddbäck, Senior Scientist at Alligator Bioscience, will present a poster entitled "ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces myeloid and T-cell dependent anti-tumor activity and synergizes with PD-1 inhibition" on Saturday, November 9.

  • Dr Karen Geboes will present data from the OPTIMIZE-1 clinical Phase 2 trial with candidate mitazalimab in the poster entitled " CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated efficacy and correlative biomarkers from the OPTIMIZE-1 trial " on Saturday, November 9.